Abstract

Galectin-3 (Gal-3), multifunctional protein plays important roles in inflammatory response, infection and fibrosis. The goal of study was to determine the association of Gal-3, immune response, clinical, biochemical, and radiographic findings with COVID-19 severity. Study included 280 COVID-19 patients classified according to disease severity into mild, moderate, severe and critical group. Cytokines, clinical, biochemical, radiographic data and peripheral blood immune cell make up were analyzed. Patients in critical group had significantly higher serum level of Gal-3, IL-1β, TNF-α, IL-12, IL-10 compared to the patients in less severe stages of disease. Strong positive correlation was detected between Gal-3 and IL-1β, moderate positive correlation between Gal-3, TNF-α and IL-12, moderate negative correlation between Gal-3, IL-10/IL-1β and IL-10/TNF-α. Moderate positive correlation noted between Gal-3 and urea, D dimer, CXR findings. Strong negative correlation detected between Gal-3 and p02, Sa02, and moderate negative correlation between Gal-3, lymphocyte and monocyte percentage. In the peripheral blood of patients with more severe stages of COVID-19 we detected significantly increased percentages of CD56 CD3+TNF-α+T cells and CD56 CD3+Gal-3+T cells and increased expression of CCR5 in PBMCs. Our results predict Gal-3 as an important marker for critical stage of COVID-19. Higher expression of Gal-3, TNF-α and CCR5 on T cells implicate on promoting inflammation and more severe form of disease.

Details

Title
Galectin-3 as an important prognostic marker for COVID-19 severity
Author
Gajovic, Nevena 1 ; Markovic, Sofija Sekulic 2 ; Jurisevic, Milena 3 ; Jovanovic, Marina 4 ; Arsenijevic, Nebojsa 1 ; Mijailovic, Zeljko 2 ; Jovanovic, Ivan 1 

 University of Kragujevac, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, Kragujevac, Serbia (GRID:grid.413004.2) (ISNI:0000 0000 8615 0106) 
 University of Kragujevac, Department of Infectious Diseases, Faculty of Medical Sciences, Kragujevac, Serbia (GRID:grid.413004.2) (ISNI:0000 0000 8615 0106) 
 University of Kragujevac, Department of Clinical Pharmacy, Faculty of Medical Sciences, Kragujevac, Serbia (GRID:grid.413004.2) (ISNI:0000 0000 8615 0106) 
 University of Kragujevac, Department of Internal Medicine, Faculty of Medical Sciences, Kragujevac, Serbia (GRID:grid.413004.2) (ISNI:0000 0000 8615 0106) 
Pages
1460
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2769878107
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.